Objective: To identify a noninvasive screening test for intestinal allograft monitoring. Summary Background Data: Intestinal allograft rejection is difficult to distinguish from other causes of diarrhea and can rapidly lead to severe exfoliation or death. Protocol biopsies are standard for allograft monitoring but may cause serious complications. No noninvasive test has shown clinical utility for monitoring of the intestinal allograft. Methods: Calprotectin levels (n ϭ 68) were measured in this pilot study from ileostomy effluent in patients with histologic evidence of acute rejection (n ϭ 12), viral enteritis (n ϭ 5), and nonspecific inflammation (n ϭ 16) and compared with those with normal allograft histology (n ϭ 35). Results: Median stool calprotectin levels from patients with rejection were significantly higher than those from patients with viral enteritis or normal biopsies ͓198 mg/kg compared with 7 and 19 mg/kg, respectively (P ϭ 0.0002)͔. Receiver operator characteristics suggest the optimal cut-off level to distinguish rejection from other diagnoses is 92 mg/kg with specificity of 77% and sensitivity of 83%. Although false-positive results occurred in 26% of patients with normal biopsies and 30% with nonspecific changes, no treated episode of acute rejection was below the cutoff. In addition, in 2 patients with serial levels, elevations in the calprotectin levels preceded histologic changes by 6 to 18 days. Conclusions: Low stool calprotectin levels correlate well with a low risk for intestinal allograft rejection. If confirmed, biopsies may be reserved in the future for confirmation of rejection, eliminating protocol biopsies, and immunosuppressive changes could potentially be made before allograft injury.
I ntestinal transplantation has become standard therapy for patients who suffer life-threatening complications from intestinal failure. 1 One of the most common clinical presentations after intestinal transplantation is diarrhea. The cause of the diarrhea may be rejection of the allograft, infectious enteritis, or toxic reaction to medications or foods. A noninvasive test to differentiate these causes is not clinically available at this time. 2 Serial endoscopic biopsy through a temporary ileostomy to obtain tissue for histology is therefore required. When mild rejection is treated promptly with additional immunosuppression, it is usually easily controlled. Delay in the treatment by just hours to days may result in progression from mild to severe exfoliative rejection, which is associated with a substantial risk of graft loss (up to 93%) and mortality (50 -70%). [3] [4] [5] [6] [7] [8] Protocol biopsies are therefore routinely performed weekly in the first 3 months after intestinal transplantation and whenever intestinal transplant recipients present with diarrhea. The histologic and endoscopic patterns of intestinal allograft rejection and viral enteritis after intestinal transplantation or in other immunocompromised patients have been reviewed elsewhere. 9 -12 Although histology may or may not be definitive in patients with infectious enteritis as the cause of diarrhea, exclusion of rejection will prevent increasing immunosuppression in these instances, which could have devastating consequences.
The problems with protocol biopsy is that a temporary ileostomy is routinely performed in most patients to facilitate easy endoscopic access, although it is not appealing to many patients and family. In addition, endoscopy is an expensive invasive procedure that may require general anesthesia in children, and biopsy is associated with a risk for complications, albeit low, such as bleeding and/or intestinal perforation in 1% to 5% of intestinal transplant recipients. 13, 14 In addition, although histology remains the gold standard for the diagnosis of acute rejection, up to 30% of biopsies are nondiagnostic. 11, 15 Recent studies have examined the role of calprotectin in the evaluation of gut inflammation and have found that it can accurately distinguish active inflammatory bowel disease (an immune mediated bowel injury) from other causes of bowel dysfunction. 16 -19 Calprotectin is a protein that has 2 subunits, each of which are part of the S100 family of proteins and comprises approximately half of the cytosolic protein in neutrophils. Calprotectin has been isolated from activated macrophages, but does not appear to be present in lympho-cytes. 20, 21 Calprotectin can be secreted extracellularly in a soluble form, but is more commonly released as a result of cell disruption or death. [22] [23] [24] Mucosal epithelial cells have also been shown to express calprotectin in their cytoplasm constitutively. Therefore, increased shedding of epithelial cells could contribute to the increased levels found in stool.
Inflammatory bowel disease (IBD) monitoring is the area with the most clinical experience in the use of stool calprotectin levels, reliably differentiating active IBD from irritable bowel syndrome and correlating with disease activity in serial measurements. 19, 25, 26 Calprotectin is a very stable compound at room temperature and can be measured within hours with a simple ELISA test, so that quick turn around of results could be used for clinical decision making, similar to allograft histology. With this background, we hypothesized that sampling for calprotectin levels in succus entericus obtained from the stomas of intestinal transplant recipients could be used as a noninvasive screening test for allograft rejection.
METHODS
This study was performed at the University of Nebraska Medical Center with the Institutional Review Board (IRB) approval including the informed consent of intestinal transplant recipients or parents of recipients in accordance with ethical standards. Intestinal biopsy samples and stool were prospectively collected for the purpose of identifying noninvasive markers for the evaluation of the intestinal allografts. This is a pilot study of 68 stool samples collected from 20 patients, between July 2003 and June 2004. All patients who were enrolled in the tissue bank during this time, underwent intestinal allograft biopsy, and had stool samples collected were included in this study. Seventeen of the 20 patients were enrolled immediately after transplantation and 3 patients were enrolled when they returned for evaluation of complications 3 to 6 years after transplantation. Eighteen of the patients were children (median age, 2; range, 1-13) and 2 were adults (ages 23 and 53 years, respectively). The median time between transplantation and stool collection was 2.5 months (range, 0 -65 months). All stool samples available from the Intestinal Transplant Tissue Bank at the University of Nebraska Medical Center that were collected at the time of any abnormal histologic diagnosis were evaluated for this study, including 12 samples in 5 patients with acute rejection, 5 samples in 3 patients with viral enteritis, and 16 samples in 11 patients with nonspecific enteritis. In addition, a selection of 35 samples from 16 patients were chosen from those with normal allograft histology. Each sample was considered independently, and calprotectin levels were compared with the associated histology of the simultaneous intestinal allograft biopsy. Histologic diagnosis was made by examination of H&E staining of slides prepared from fixed allograft biopsy specimens, using the standard criteria developed by pathologists experienced in intestinal allograft histology. 12 Fluid samples were obtained from the ileostomy within 24 hours of a therapeutic or protocol biopsy and frozen at Ϫ80°C in 1.5-mL aliquots until batch sample analysis.
Blinded specimens were used for duplicate measurement of calprotectin levels. Calprotectin was detected and quantified using CALPREST ELISA kit (NovaTec Immundiagnostica, Germany) according to manufacturer's instructions. The optical density (OD) of the samples is measured at 405 nm with a microtiter plate reader and then plotted as the log value.
Data are presented as the median (range) unless otherwise stated. Comparisons of the median calprotectin levels of each of the 4 groups were made using the Kruskal-Wallis test and the Dunn's multiple comparison post test. P Ͻ 0.05 was considered significant. Receiver-operator curves were generated to analyze the optimal cutoff levels. Graph Pad Prism software was used to perform the statistical analysis. Figure 1 summarizes the distribution of the calprotectin values in each of the 4 diagnostic groups. The median value (and 25th/75th quartile values) for calprotectin for each of the 4 groups (acute rejection, viral enteritis, nonspecific enteritis, and normal) were 198 (103/251), 7 (6.25/35), 57 (17/106), and 19 (6.25/85) mg/L, respectively. Overall median values of these groups are significantly different (P ϭ 0.0002), and post-test evaluation reveals the differences to be between the rejection and normal groups (P Ͻ 0.001) and the rejection and viral enteritis groups (P Ͻ 0.01). Receiver-operator characteristics suggest an optimal cutoff of 92 mg/L with 77% specificity and 83% sensitivity in distinguishing rejection from specimens without rejection (Fig. 2) . The negative predictive value of calprotectin for clinically relevant acute rejection was excellent. Only 1 patient in this pilot study with a calprotectin level below the optimal cutoff had histologic changes consistent with rejection, and this patient was not treated with any additional immunosuppression due to the absence of symptoms and repeat biopsy 24 hours later revealing no evidence of rejection.
RESULTS
The positive predictive value for calprotectin appears reasonable for a screening test. Seventy-six percent of pa- tients with normal biopsies, 100% with viral enteritis, and 70% with nonspecific enteritis had calprotectin levels below the cutoff (Fig. 1) . Patients with nonspecific enteritis on histology were the most likely to have increased calprotectin levels (median level ϭ 57 mg/dL).
Of the 13 samples with high calprotectin levels without histologic signs of rejection (ie, normal or nonspecific enteritis), 30% either preceded or followed histologic resolution of an episode of acute rejection; 3 samples were obtained from 2 different patients 1 week to 18 days before the histologic diagnosis of acute rejection ( Fig. 3) and one was from one of the same patients 1 week after treatment for acute rejection. Nine additional samples from 7 patients had high calprotectin levels (Ͼ92 mg/dL), and the clinical situation of these patients included severe pericarditis without diarrhea in 1 patient, severe skin rash and diarrhea attributed to a drug reaction in 1 patient, 2 samples from 1 patient who was clinically well, diarrhea of unclear etiology (in 2 patients; resolved without change in immunosuppression in 1 and resolved with elevation of baseline tacrolimus levels in 1), 1 patient in the first 10 days after transplant, and 1 sample obtained several days after ostomy revision in 1 patient.
DISCUSSION
In renal or liver allograft recipients, routine protocol biopsies are not performed in most centers. Instead, screening tests such as creatinine for recipients of renal allografts and liver function tests for recipients of liver allografts are used for clinical monitoring. A recent review of intestinal allograft monitoring demonstrated that no such test is clinically available for screening after intestinal transplantation. 2 Although elevations in screening tests for renal and liver allografts often prompt a biopsy to confirm rejection before treatment, other causes for the elevations such as dehydration, biliary leak, or drug toxicity may be the etiology of the abnormal values. Among the tests that have been previously investigated for allograft monitoring, citrulline has been the most extensively studied. Although low citrulline levels reflect poor intestinal function, they are routinely low after transplantation for the first month or two, which is the time of highest risk for the development of rejection. 27, 28 The most concerning aspect of citrulline as a potential screening test is that once levels normalizes after transplantation, they do not become decreased/abnormal until substantial injury to the graft has occurred. 28 This suggests citrulline levels may correlate well with severe rejection episodes, but may not be useful in identifying mild to moderate rejection episodes when they are still reversible. In addition, citrulline levels vary with body surface area such that levels in children are routinely below the normal established for adults even in the presence of normal intestinal function. 27 In light of the demographics of intestinal transplantation with more than 50% performed in children and the limitations noted, citrulline has not to date shown clinical utility.
The possible role of calprotectin in solid organ rejection has been suggested previously. In kidney and lung allografts, macrophages with increased membrane expression of the calprotectin proteins appear in the allograft during acute . Two of these patients showed elevations of calprotectin levels in 3 ostomy effluent samples obtained prior to identifiable changes in histology (signified by the *), ie, 150 mg/L (*) in patient 2 when allograft histology showed nonspecific enteritis and 1 week before the peak of 425 (2) measured at the time moderate rejection was diagnosed; and 50 mg/L (*) in patient 3, who previously had undetectable levels, but increased to 225 mg/L (2) at the time the histology revealed acute rejection.
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Calprotectin rejection episodes. 29 -31 The specificity of the increased membrane expression of calprotectin for allograft rejection is not clear, since experiments using cultured alveolar macrophage also show increased membrane expression after stimulation with bacterial lipopolysaccharide. 31 In the only published report examining an intestinal transplant recipient, elevations in serum calprotectin levels occurred simultaneous with or immediately before 3 clinical episodes of rejection and did not correspond to elevations of the patients white blood cell count. 32 The role of calprotectin levels in stool has not been previously examined in any solid organ transplant recipient.
In this pilot study, we examined, in a blinded manner, representative ileostomy samples from 20 small bowel transplant recipients. The findings of this report suggest that low calprotectin levels (Ͻ92 mg/L) uniformly defined patients without acute rejection. In the only patient in this pilot study with histologic evidence of acute rejection and a low calprotectin level, repeat biopsy was performed within 24 hours due to the absence of diarrhea, and the histology of the repeat biopsy was normal. This patient was correctly identified by the calprotectin level. Although he was spared additional immunosuppression, he required repeat endoscopy and biopsy with the associated risks due to the initial histology suggesting rejection.
Calprotectin levels in this study appear to be useful for monitoring intestinal allografts, similar in efficacy to creatinine and liver function studies for monitoring of renal or liver allografts and similar to the gold standard, allograft histology (ie, 30% nondiagnostic). Here we found 24% of patients with normal histology and 31% with nonspecific enteritis had elevations above the threshold for calprotectin, whereas no patient treated for rejection had a low level. A therapeutic biopsy to confirm or exclude rejection reserved for the onefourth of recipients with diarrhea and elevated stool calprotectin would be a tremendous decrease in biopsies compared with current practice and would lead to significant savings in costs, manpower, and potential risk.
Several areas require further investigation. As noted, the early postoperative period requires further examination since elevation of calprotectin levels in the absence of acute rejection was identified in 1 patient, likely the result of preservation injury and within days of ostomy revision in a second patient. Of note, the immediate posttransplant elevation above the cutoff level for calprotectin was brief and rapid normalization in this patient within 2 weeks of intestinal transplantation was observed in contrast to the studies of plasma citrulline where normalization took on average 45 days. Although the current data set for serial observations is limited and the results must be confirmed, this pilot study also suggests that calprotectin levels may be more sensitive than histology as a marker for immunologic activation in the early or prerejection time points. Serial monitoring with concurrent biopsy is needed to determine how uniformly the increase in calprotectin levels occur before the histologic changes as seen in 2 patients in this study and depicted in Figure 3 . If confirmed, these findings suggest that monitoring of calprotectin levels may provide an opportunity to adjust immunosuppression before allograft injury. Finally, this pilot study did not find any elevations in calprotectin levels in patients with defined viral infections, although the number of patients was limited. Since this is the group of patients that are most likely to be harmed by an increase in immunosuppression, it is particularly useful that calprotectin levels were uniformly low in this group. Further studies will need to include patients with rotavirus, Norwalk virus, and Clostridium difficile colitis as these causes of infectious diarrhea were not represented in this study.
There are some limitations to the interpretation of the results of this study. First, this was a retrospective analysis of selected patient samples with known diagnosis, although the individuals performing the assays were blinded as to the source of the samples. A prospective study to examine the risk of using calprotectin for screening as an alternative to routine protocol biopsy is currently underway. This prospective study will include serial measurements in all enrolled patients and assess all episodes of viral enteritis to answer many of the questions raised above.
In conclusion, calprotectin is a promising clinical screening test for intestinal allograft rejection. Low levels of calprotectin correlate extremely well with a low risk for allograft rejection and likely will allow for elimination of protocol biopsies in a large proportion of patients who are otherwise clinically well. If the clinical utility of this marker is confirmed in currently ongoing prospective validation studies, future studies will be aimed at adjusting immunosuppression at the time of increased immune activation and prior to allograft injury.
